These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19648126)

  • 1. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
    Syversen SW; Goll GL; van der Heijde D; Landewé R; Lie BA; Odegård S; Uhlig T; Gaarder PI; Kvien TK
    Ann Rheum Dis; 2010 Feb; 69(2):345-51. PubMed ID: 19648126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.
    van Gaalen FA; van Aken J; Huizinga TW; Schreuder GM; Breedveld FC; Zanelli E; van Venrooij WJ; Verweij CL; Toes RE; de Vries RR
    Arthritis Rheum; 2004 Jul; 50(7):2113-21. PubMed ID: 15248208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis.
    Kaltenhäuser S; Pierer M; Arnold S; Kamprad M; Baerwald C; Häntzschel H; Wagner U
    Rheumatology (Oxford); 2007 Jan; 46(1):100-4. PubMed ID: 16728439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
    Snir O; Widhe M; von Spee C; Lindberg J; Padyukov L; Lundberg K; Engström A; Venables PJ; Lundeberg J; Holmdahl R; Klareskog L; Malmström V
    Ann Rheum Dis; 2009 May; 68(5):736-43. PubMed ID: 18635594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study.
    Karlson EW; Chibnik LB; Cui J; Plenge RM; Glass RJ; Maher NE; Parker A; Roubenoff R; Izmailova E; Coblyn JS; Weinblatt ME; Shadick NA
    Ann Rheum Dis; 2008 Mar; 67(3):358-63. PubMed ID: 17666451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
    Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
    Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
    Syversen SW; Gaarder PI; Goll GL; Ødegård S; Haavardsholm EA; Mowinckel P; van der Heijde D; Landewé R; Kvien TK
    Ann Rheum Dis; 2008 Feb; 67(2):212-7. PubMed ID: 17526555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking, the HLA-DRB1 shared epitope and ACPA fine-specificity in Koreans with rheumatoid arthritis: evidence for more than one pathogenic pathway linking smoking to disease.
    Fisher BA; Bang SY; Chowdhury M; Lee HS; Kim JH; Charles P; Venables P; Bae SC
    Ann Rheum Dis; 2014 Apr; 73(4):741-7. PubMed ID: 23505239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis.
    Reneses S; González-Escribano MF; Fernández-Suárez A; Pestana L; Davila B; Wichmann I; García A
    J Rheumatol; 2009 Jun; 36(6):1143-9. PubMed ID: 19411391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
    Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
    Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.